

Molnupiravir Checklist Tool for Prescribers:

Patient Eligibility

Patient Name: _____ DOB: _____

- Current diagnosis of mild to moderate COVID-19¹
- Age ≥ 18 years
- Alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate
- High risk criteria² met
- Symptom onset within 5 days*
- Not hospitalized due to COVID-19

*Prescriber is encouraged to include a note to the pharmacist in the prescription stating: Please fill prescription by _____ [insert date] _____. This prescription fill by date is within 5 days from symptom onset and complies with the patient eligibility criteria under the EUA.

¹ <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:~:text=Patients%20with%20mild%20illness%20may,on%20exertion%2C%20or%20abnormal%20imaging>

² <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>

Molnupiravir Checklist Tool for Prescribers: Prescriber Requirements

1. All Patients

- Provide electronic or hard copy of patient fact sheet
 - Document that patient has received an electronic or hard copy of the patient fact sheet³
 - Review the information contained within the patient factsheet with the patient and counsel patient on the known and potential benefits and risks of MOV
 - Advise patients on need for contraception use as appropriate
 - Females of childbearing potential treated: should use a reliable method of contraception correctly and consistently, as applicable, for the duration of treatment and for 4 days after the last dose of molnupiravir
 - Males of reproductive potential treated: if sexually active with females of childbearing potential, should use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after the last dose
 - The prescribing healthcare provider and/or the provider's designee must report all medication errors and serious adverse events potentially related to molnupiravir within 7 calendar days from the healthcare provider's awareness of the event

2. Individuals of Childbearing Potential

- Assess whether pregnant or not
 - Report of LMP in an individual who has regular menstrual cycles, uses a reliable method of contraception correctly and consistently or has had a negative pregnancy test
 - Negative pregnancy test (recommended but not required if other criteria are not met)
- If pregnant:
 - Counsel the patient regarding the known and potential benefits and potential risks of molnupiravir use during pregnancy
 - Document that the patient is aware of the known and potential benefits and potential risks of molnupiravir use during pregnancy
 - Make the individual aware of the pregnancy registry at <https://covid-pr.pregistry.com> or 1-800-616-3791
- If not pregnant:
 - Make the individual aware of the pregnancy registry program and encourage them to participate should they become pregnant

³ How and where documentation occurs is at the discretion of the prescribing health care provider and their clinical site.